Table 1.

Studies investigating cannabinoid-mediated neuroprotection in models of glaucoma.

Drug	Delivery	Study	Model	Neuroprotective effect versus vehicle (treatment versus control)
THC	IP	Crandall et al., 2007 [68]	Episcleral vein cauterization	~20–40% increase (10–20% loss)
THC	IV	El-Remessy et al., 2003 [69]	Intravitreal NMDA	~9% of vehicle∗
CBD	IV	El-Remessy et al., 2003 [69]	Intravitreal NMDA	~4% of vehicle∗
WIN 55,212-2	Topical	Pinar-Sueiro et al., 2013 [70]	Ischemia-reperfusion (high IOP)	9.88% increase (2.45% loss)
MetAEA	IVit	Nucci et al., 2007 [44]	Ischemia-reperfusion (high IOP)	18.6% increase (9.4% loss)
URB597	IP	Nucci et al., 2007 [44]	Ischemia-reperfusion (high IOP)	15.1% increase (12.9% loss)
URB597	IP	Slusar et al., 2013 [71]	Axotomy	1 week, 19.5% increase (27.9% loss) 2 weeks, 22.7% increase (58.9% loss)
Celecoxib	IP	Sakai et al., 2009 [72]	Ischemia-reperfusion (high IOP)	25.8% increase (39.1% loss)
SC-58236	IP	Ju et al., 2003 [45]	Ischemia-reperfusion (high IOP)	Central, 28.4% increase (27.3% loss) Peripheral, 28% increase (26.8% loss)

IP, intraperitoneal; IV, intravenous; IVit, intravitreal; ^∗study reported quantification of tunnel positive cells only.